Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (S Form 20-F, which are both expected to be filed with the SEC in February 2020 in continuation o statements made, to the public in the future by or on behalf of Novo Nordisk, may contain forw ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘target’ and other words an performance identify forward-looking statements. Examples of such forward-looking statements • Statements of targets, plans, objectives or goals for future operations, including those relat and product approvals as well as cooperation in relation thereto, • Statements containing projections of or targets for revenues, costs, income (or loss), earnin financial measures, • Statements regarding future economic performance, future actions and outcome of conting • Statements regarding the assumptions underlying or relating to such statements. These statements are based on current plans, estimates and projections. By their very nature, Novo Nordisk cautions that a number of important factors, including those described in this pre forward-looking statements. Factors that may affect future results include, but are not limited to, global as well as local polit delay or failure of projects related to research and/or development, unplanned loss of patents, terminations, government-mandated or market-driven price decreases for Novo Nordisk’s produ ability to successfully market current and new products, exposure to product liability and legal p thereof, including on reimbursement, intellectual property protection and regulatory controls on ethical marketing practices, investments in and divestitures of domestic and foreign companies, and failure to maintain a culture of compliance. For an overview of some, but not all, of the risks that could adversely affect Novo Nordisk’s res the overview of risk factors in ‘Managing risks to protect value’ on pp 33-35 of the Annual Repo Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update a result of new information, future events or otherwise. Important drug information • Victoza® is approved for the management of type 2 diabetes only • Saxenda® is approved in the USA and the EU for the treatment of obesity only
Download PDF file